Doximity upgraded to Outperform from In Line at Evercore ISI
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 09 2025
0mins
Should l Buy DOCS?
Analyst Upgrade: Evercore ISI analyst Elizabeth Anderson has upgraded Doximity's rating to Outperform with a price target increase from $50 to $70, citing conservative fiscal 2026 guidance.
Growth Potential: The firm's analysis suggests that Doximity's formulary business is expected to grow at least mid-single-digits in fiscal 2026, indicating strong potential for the company's overall performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DOCS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DOCS
Wall Street analysts forecast DOCS stock price to rise
18 Analyst Rating
14 Buy
4 Hold
0 Sell
Strong Buy
Current: 24.710
Low
25.00
Averages
42.75
High
63.00
Current: 24.710
Low
25.00
Averages
42.75
High
63.00
About DOCS
Doximity, Inc. provides a digital platform for the United States medical professionals. It offers marketing, hiring, and workflow solutions to pharmaceutical manufacturers, health systems, medical recruiting firms, and other healthcare companies. Its marketing solutions enable its pharmaceutical and health system customers to get the right content, services, and peer connections to the right medical professionals through a variety of modules. Its hiring solutions provide digital recruiting capabilities to health systems and medical recruiting firms, enabling them to identify, connect with, and hire from its network of both active and passive medical professional candidates, who might otherwise be missed through traditional recruiting channels. Its workflow solutions include its telehealth, on-call scheduling, and AI-powered workflow tools, are designed to help clinicians streamline their clinical workflow, reduce their administrative burden, and connect with patients and colleagues.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
DOXIMITY INC: TRUIST SECURITIES LOWERS RATING TO HOLD FROM BUY; REDUCES TARGET PRICE TO $29 FROM $37
Company Overview: Doximity, a healthcare technology company, has made significant changes to its financial outlook.
Target Price Adjustment: The company has cut its target price from $37 to $29, reflecting a more conservative market expectation.
See More
Doximity CFO Anna Bryson Resigns Amid Transition
- Executive Departure: Doximity accepted the resignation of CFO Anna Bryson on April 13, 2026, following her medical leave, indicating potential challenges in executive stability that may affect investor confidence.
- Interim Financial Leadership: Since February 3, 2026, Chief Accounting Officer Siddharth Sitaram has been serving as the interim principal financial and accounting officer until a new CFO is appointed, which could lead to delays in financial decision-making and impact strategic execution.
- Guidance Reaffirmation: Doximity reaffirmed its previously issued guidance for Q4 and the full fiscal year ending March 31, 2026, demonstrating the company's intent to maintain stable financial expectations amid uncertain market conditions, aiming to bolster investor confidence.
- Uncertain Growth Outlook: Despite the reaffirmation of guidance, the market outlook for Doximity remains murky, which could affect its stock performance, prompting investors to closely monitor the upcoming CFO appointment and its implications for the company's strategy.
See More
Market Volatility Following Anthropic's Managed Agents Announcement
- AI Disruption: Anthropic's announcement of Managed Agents has sparked investor concerns about potential disruptions to existing SaaS business models, leading to notable declines in stocks such as Doximity, Guidewire, and Intuit, which fell by 3%, 5%, and 5%, respectively.
- Overreaction in Market: Despite the severe market reaction to AI agents, analysts suggest that significant price drops may present buying opportunities for high-quality stocks, particularly as investors look for long-term value amidst volatility.
- Health Catalyst Volatility: Health Catalyst has experienced 51 moves greater than 5% over the past year, with its current share price at $1.03, representing a 77.3% decline from its 52-week high of $4.52, indicating cautious market sentiment regarding its future prospects.
- Geopolitical Tensions: Recent geopolitical tensions have escalated, pushing oil prices to new highs, which could increase business costs and trigger inflation, further impacting global economic growth, necessitating investor vigilance on related developments.
See More
Doximity Reports Weak Earnings, Stock Down 31.2%
- Earnings Beat: Doximity reported revenues of $185.1 million, a 9.8% year-over-year increase, exceeding analyst expectations by 2%, yet the revenue and EBITDA guidance for the next quarter fell short, leading to negative market sentiment.
- Significant Stock Decline: Following the earnings report, Doximity's stock plummeted by 31.2%, currently trading at $22.93, indicating investor concerns regarding future growth prospects.
- Industry Performance Comparison: Within the vertical software sector, Doximity's performance was notably weak, as the overall industry reported a 2.5% revenue beat in Q4, highlighting Doximity's struggle to keep pace with sector growth.
- Shifting Market Sentiment: Amid rising geopolitical risks, investor confidence in the software sector has waned, and Doximity's earnings report failed to alleviate concerns about its future profitability.
See More
DOXIMITY INC: EVERCORE ISI Downgrades to In Line from Outperform; Lowers Target Price to $25 from $30
Company Overview: Doximity, a healthcare technology company, has made significant changes to its financial outlook.
Financial Adjustments: The company has cut its target price from $30 to $25, indicating a shift in market expectations.
See More
Profitable Companies May Not Last
- Caution on GE Healthcare: GE Healthcare's annual revenue growth of only 2.7% over the past two years significantly lags behind other healthcare firms, indicating core business struggles that may necessitate acquisitions for growth stimulation, with a current share price of $70.42 and a forward P/E of 14.2x.
- Northern Trust's Slow Growth: Northern Trust has experienced muted annual revenue growth of 5.8% over the last five years, with its EPS growth of 9.3% falling short of peer averages, trading at $142.24 per share and a forward P/E of 13x, reflecting demand lagging behind financial performance.
- Doximity's Strong Performance: Doximity boasts an impressive annual revenue growth of 29.3% over the past five years, showcasing market share gains, and its user-friendly software allows clients to quickly ramp up spending, with a current stock price of $22.94 and a forward price-to-sales ratio of 6.7x, indicating robust cash flow and investment flexibility.
- High-Quality Stocks in Focus: While many profitable companies exist, not all are poised for sustained growth; analysis reveals that only a select few can maintain high-quality growth across various market conditions, prompting investors to focus on these potential winners.
See More
DOXIMITY INC: TRUIST SECURITIES LOWERS RATING TO HOLD FROM BUY; REDUCES TARGET PRICE TO $29 FROM $37
Company Overview: Doximity, a healthcare technology company, has made significant changes to its financial outlook.
Target Price Adjustment: The company has cut its target price from $37 to $29, reflecting a more conservative market expectation.
See More
Doximity CFO Anna Bryson Resigns Amid Transition
- Executive Departure: Doximity accepted the resignation of CFO Anna Bryson on April 13, 2026, following her medical leave, indicating potential challenges in executive stability that may affect investor confidence.
- Interim Financial Leadership: Since February 3, 2026, Chief Accounting Officer Siddharth Sitaram has been serving as the interim principal financial and accounting officer until a new CFO is appointed, which could lead to delays in financial decision-making and impact strategic execution.
- Guidance Reaffirmation: Doximity reaffirmed its previously issued guidance for Q4 and the full fiscal year ending March 31, 2026, demonstrating the company's intent to maintain stable financial expectations amid uncertain market conditions, aiming to bolster investor confidence.
- Uncertain Growth Outlook: Despite the reaffirmation of guidance, the market outlook for Doximity remains murky, which could affect its stock performance, prompting investors to closely monitor the upcoming CFO appointment and its implications for the company's strategy.
See More
Market Volatility Following Anthropic's Managed Agents Announcement
- AI Disruption: Anthropic's announcement of Managed Agents has sparked investor concerns about potential disruptions to existing SaaS business models, leading to notable declines in stocks such as Doximity, Guidewire, and Intuit, which fell by 3%, 5%, and 5%, respectively.
- Overreaction in Market: Despite the severe market reaction to AI agents, analysts suggest that significant price drops may present buying opportunities for high-quality stocks, particularly as investors look for long-term value amidst volatility.
- Health Catalyst Volatility: Health Catalyst has experienced 51 moves greater than 5% over the past year, with its current share price at $1.03, representing a 77.3% decline from its 52-week high of $4.52, indicating cautious market sentiment regarding its future prospects.
- Geopolitical Tensions: Recent geopolitical tensions have escalated, pushing oil prices to new highs, which could increase business costs and trigger inflation, further impacting global economic growth, necessitating investor vigilance on related developments.
See More
Doximity Reports Weak Earnings, Stock Down 31.2%
- Earnings Beat: Doximity reported revenues of $185.1 million, a 9.8% year-over-year increase, exceeding analyst expectations by 2%, yet the revenue and EBITDA guidance for the next quarter fell short, leading to negative market sentiment.
- Significant Stock Decline: Following the earnings report, Doximity's stock plummeted by 31.2%, currently trading at $22.93, indicating investor concerns regarding future growth prospects.
- Industry Performance Comparison: Within the vertical software sector, Doximity's performance was notably weak, as the overall industry reported a 2.5% revenue beat in Q4, highlighting Doximity's struggle to keep pace with sector growth.
- Shifting Market Sentiment: Amid rising geopolitical risks, investor confidence in the software sector has waned, and Doximity's earnings report failed to alleviate concerns about its future profitability.
See More
DOXIMITY INC: EVERCORE ISI Downgrades to In Line from Outperform; Lowers Target Price to $25 from $30
Company Overview: Doximity, a healthcare technology company, has made significant changes to its financial outlook.
Financial Adjustments: The company has cut its target price from $30 to $25, indicating a shift in market expectations.
See More
Profitable Companies May Not Last
- Caution on GE Healthcare: GE Healthcare's annual revenue growth of only 2.7% over the past two years significantly lags behind other healthcare firms, indicating core business struggles that may necessitate acquisitions for growth stimulation, with a current share price of $70.42 and a forward P/E of 14.2x.
- Northern Trust's Slow Growth: Northern Trust has experienced muted annual revenue growth of 5.8% over the last five years, with its EPS growth of 9.3% falling short of peer averages, trading at $142.24 per share and a forward P/E of 13x, reflecting demand lagging behind financial performance.
- Doximity's Strong Performance: Doximity boasts an impressive annual revenue growth of 29.3% over the past five years, showcasing market share gains, and its user-friendly software allows clients to quickly ramp up spending, with a current stock price of $22.94 and a forward price-to-sales ratio of 6.7x, indicating robust cash flow and investment flexibility.
- High-Quality Stocks in Focus: While many profitable companies exist, not all are poised for sustained growth; analysis reveals that only a select few can maintain high-quality growth across various market conditions, prompting investors to focus on these potential winners.
See More
